Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
CONCLUSIONS: Homocysteine could be a potential biomarker to discriminate the effects of dual and single antiplatelet therapy in female patients with minor ischemic stroke or high-risk transient ischemic attack.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.
PMID: 31941381 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Li J, Wang Y, Li H, Zuo Z, Lin J, Wang A, Zhao X, Liu L, Wang Y, CHANCE Investigators* Tags: Arterioscler Thromb Vasc Biol Source Type: research
More News: Arteriosclerosis | Aspirin | Biology | Bleeding | Cardiology | China Health | Clinical Trials | Clopidogrel | Ischemic Stroke | Plavix | Stroke | Thrombosis | Women